In the next few weeks I plan to highlight under-appreciated and under-followed biotech companies-the first of which is OncoGenex (OGXI). These names represent a significant profit potential for those who have a longer-term perspective. Too many traders have a very short hold period and, in turn, miss opportunities that Endocyte (ECYT) or Pharmacyclics (PCYC) can give their portfolio over a period of 1-3 years.
As the first installment in this series of CEO interviews, I would like to introduce OncoGenex CEO Scott Cormack and show how he has built a unique cancer biotechnology company. This exclusive interview with Mr. Cormack makes a case that OncoGenex is a bargain-buy at today's price levels.
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: